Market Overview:
The global PARP inhibitor biomarkers testing product market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for personalized medicine, and technological advancements in biomarkers testing products. Based on type, the global PARP inhibitor biomarkers testing product market is segmented into testing kits and testing assays. The Testing assay segment is further sub-segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray assay, and others. Based on application, the global PARP inhibitor biomarkers testing product market is divided into hospital laboratories, clinic laboratories, research institutes/academic institutions Laboratories,,and others segments which include point-of-care settings such as doctor’s offices or clinics).
Product Definition:
PARP inhibitors are a class of drugs that block an enzyme called poly (ADP-ribose) polymerase. This enzyme helps cells repair DNA damage. PARP inhibitors are used to treat some types of cancer, including breast cancer and ovarian cancer.
Testing Kits:
The global testing kits, it's usage and growth factor in PARP inhibitor biomarkers Testing Products market size was valued at USD 1.0 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period.
Testing Assays:
testing assays are used for the detection of biomolecules such as proteins, peptides, and DNA in a sample. It is an analytical procedure that involves the use of various techniques to measure or detect a particular substance or phenomenon. In this case, it is used to detect PARP inhibitors in biological samples such as urine and plasma.
U.
Application Insights:
The others application segment held the largest share of more than 50.0% in 2017. The other applications include research laboratories, diagnostic centers and patient care facilities. Increasing demand for these services among patients with acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC) is expected to drive the product demand in clinics & hospitals over the forecast period.
Parp inhibitors are widely used for treating various cancers such as breast cancer, prostate cancer, skin tumor cancers including melanoma and keratoacanthoma, bladder tumors, head neck tumors and gastric adenocarcinomas owing to their ability to block PARP enzyme activity thus exhibiting anti-cancer activity against these diseases without any harmful effects on normal cells or tissues at therapeutic concentrations.
Regional Analysis:
North America dominated the global market in 2017. This is due to the presence of key players, such as Alteogen Inc., and small number of molecules developed for clinical use. The region will retain its dominant position throughout the forecast period owing to factors such as favorable reimbursement policies, well-established healthcare infrastructure and high patient awareness levels coupled with relatively higher healthcare spending levels in North America compared to other regions.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing prevalence of cancer and other diseases leading to an increase in demand for PARP inhibitors across this region. Moreover, growing investments by major pharmaceutical companies are anticipated to boost growth during the forecast period. For instance, Sun Pharma & Merck Ltd.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for PARP inhibitor biomarkers testing product market. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide and it is estimated that by 2030, there will be about 21 million new cases and 13 million deaths due to cancer every year. This will create a huge demand for PARP inhibitors biomarkers testing products, which will help in early diagnosis and treatment of cancers.
- Rising awareness about personalized medicine: There is a growing trend towards personalized medicine, where treatments are tailored according to the individual’s genetic makeup. This has led to an increase in demand for PARP inhibitors biomarkers testing products as they can help in identifying patients who are likely to respond positively to these drugs.
- Technological advancements: The development of novel technologies such as next-generation sequencing (NGS) has helped in improving accuracy and speed of PARP inhibitors biomarkers testing products, thus driving their growth globally. Additionally, NGS also helps in detecting rare mutations which can lead to better treatment outcomes for patients with cancer.
Scope Of The Report
Report Attributes
Report Details
Report Title
PARP Inhibitor Biomarkers Testing Product Market Research Report
By Type
Testing Kits, Testing Assays
By Application
Hospital, Clinic, Others
By Companies
Myriad Genetics, Inc., Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., BPS Bioscience, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global PARP Inhibitor Biomarkers Testing Product Market Report Segments:
The global PARP Inhibitor Biomarkers Testing Product market is segmented on the basis of:
Types
Testing Kits, Testing Assays
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Myriad Genetics, Inc.
- Hoffmann-La Roche AG
- Invitae Corporation
- NeoGenomics Laboratories, Inc.
- BPS Bioscience, Inc.
Highlights of The PARP Inhibitor Biomarkers Testing Product Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Testing Kits
- Testing Assays
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PARP Inhibitor Biomarkers Testing Product Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PARP inhibitor biomarkers testing product is a diagnostic tool that can be used to identify individuals who may be at risk for developing cancer due to the presence of PARP inhibitors in their blood.
Some of the major players in the parp inhibitor biomarkers testing product market are Myriad Genetics, Inc., Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., BPS Bioscience, Inc..
The parp inhibitor biomarkers testing product market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 PARP Inhibitor Biomarkers Testing Product Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 PARP Inhibitor Biomarkers Testing Product Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 PARP Inhibitor Biomarkers Testing Product Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the PARP Inhibitor Biomarkers Testing Product Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global PARP Inhibitor Biomarkers Testing Product Market Size & Forecast, 2020-2028 4.5.1 PARP Inhibitor Biomarkers Testing Product Market Size and Y-o-Y Growth 4.5.2 PARP Inhibitor Biomarkers Testing Product Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Testing Kits
5.2.2 Testing Assays
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global PARP Inhibitor Biomarkers Testing Product Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 PARP Inhibitor Biomarkers Testing Product Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Testing Kits
9.6.2 Testing Assays
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Testing Kits
10.6.2 Testing Assays
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Testing Kits
11.6.2 Testing Assays
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Testing Kits
12.6.2 Testing Assays
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Testing Kits
13.6.2 Testing Assays
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 PARP Inhibitor Biomarkers Testing Product Market: Competitive Dashboard
14.2 Global PARP Inhibitor Biomarkers Testing Product Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Myriad Genetics, Inc.
14.3.2 Hoffmann-La Roche AG
14.3.3 Invitae Corporation
14.3.4 NeoGenomics Laboratories, Inc.
14.3.5 BPS Bioscience, Inc.